During the period of event accrual , vorapaxar was associated with a @ % reduction in the composite of cardiovascular death , myocardial infarction , or stroke when used with clopidogrel ( hazard ratio -LSB- HR -RSB- @ ; @ % CI @-@ @ ) and a @ % reduction when used without clopidogrel ( HR @ ; @ % CI @-@ @ ) ( interaction ; P = @ ) .